FindTrial
Sign In

Role of Metabolic syndrome in Breast Cancer

Metabolic Syndrome and Its Components in Breast Cancer: A Prospective Case-Series Study of Association with Breast Cancer Molecular Subtypes - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/111610
Enrollment
300
Registered
2026-06-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

Intervention1: Nil: Nil

Sponsors

Chennai Breast Centre Private Limited
Lead Sponsor
SHARANA TRUST
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed invasive breast cancer (all histological types), histologically confirmed by core needle biopsy or excision biopsy. 2. Presentation either screen-detected (via the tomosynthesis mammography programme at Chennai Breast Centre) or symptomatic. 3. Complete IHC panel available or planned: ER, PR, HER2 (with reflex ISH if HER2 2+), Ki-67. 4. No prior systemic or local treatment for the current breast cancer. 5. No known prior invasive cancer in the preceding 5 years (non-melanoma skin cancer excepted). 6. Willing and able to provide written informed consent in Tamil or English.

Exclusion criteria

Exclusion criteria: 1. Ductal carcinoma in situ (DCIS) without invasive component. (May be retained as a separate sub-analysis if numbers permit.) 2. Pregnancy or active lactation at time of diagnosis. 3. Established Type 1 Diabetes Mellitus (independent metabolic distortion not comparable to MetS). 4. Active systemic disease independently distorting metabolic parameters: renal failure on dialysis, hepatic cirrhosis (Child B/C), active SLE on high-dose steroids. 5. Long-term medications with major metabolic effects: oral corticosteroids ( >3 months), antipsychotics (clozapine, olanzapine), or immunosuppressants that cause metabolic syndrome. 6. Inability to undergo DEXA scan (implants that interfere; extreme body habitus beyond scanner table limit). 7. Incomplete IHC panel after repeat attempt (subtype cannot be assigned).

Design outcomes

Primary

MeasureTime frame
Homeostatic Model Assessment of Insulin ResistanceTimepoint: 1 year—

Secondary

MeasureTime frame
Prognostication of disease based on primary end pointTimepoint: 24 months—

Countries

India

Contacts

Public ContactDr Selvi Radhakrishna

Chennai Breast Centre Private Limited

academicscbc1@gmail.com9790914876

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026